Abdullah Al‐Dhfyan
About
Abdullah Al‐Dhfyan is a scholar working on Organic Chemistry, Molecular Biology and Oncology.
According to data from OpenAlex, Abdullah Al‐Dhfyan has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Organic Chemistry, 17 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Abdullah Al‐Dhfyan's work include Synthesis and biological activity (22 papers), Synthesis and Characterization of Heterocyclic Compounds (11 papers) and Synthesis and Biological Evaluation (11 papers). Abdullah Al‐Dhfyan is often cited by papers focused on Synthesis and biological activity (22 papers), Synthesis and Characterization of Heterocyclic Compounds (11 papers) and Synthesis and Biological Evaluation (11 papers). Abdullah Al‐Dhfyan collaborates with scholars based in Saudi Arabia, Egypt and Qatar. Abdullah Al‐Dhfyan's co-authors include Hesham M. Korashy, Ali Alhoshani, M. A. Bhat, Hatem A. Abdel‐Aziz, Faiyaz Shakeel, Fars K. Alanazi, Mohamed A. Al‐Omar, Wagdy M. Eldehna, Hazem A. Ghabbour and Nazrul Haq and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and British Journal of Cancer.
In The Last Decade
Abdullah Al‐Dhfyan
47 papers receiving 1.1k citations
Peers
Abdullah Al‐Dhfyan
Riccardo Baruchello Italy
Riccardo Rondanin Italy
Mariusz Mojzych Poland
Ahmed H.E. Hassan Egypt
San‐Qi Zhang China
Subhas S. Karki India
Jacques Fahy France
Bahaa Elgendy United States
Haoliang Yuan China
Dmitry A. Skvortsov Russia
Citations per year, relative to Abdullah Al‐Dhfyan Abdullah Al‐Dhfyan (= 1×)
peers
Riccardo Baruchello
Countries citing papers authored by Abdullah Al‐Dhfyan
Since
Specialization
Citations
This map shows the geographic impact of Abdullah Al‐Dhfyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdullah Al‐Dhfyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdullah Al‐Dhfyan more than expected).
Fields of papers citing papers by Abdullah Al‐Dhfyan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Abdullah Al‐Dhfyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdullah Al‐Dhfyan. The network helps show where Abdullah Al‐Dhfyan may publish in the future.
Co-authorship network of co-authors of Abdullah Al‐Dhfyan
This figure shows the co-authorship network connecting the top 25 collaborators of Abdullah Al‐Dhfyan. A scholar is included among the top collaborators of Abdullah Al‐Dhfyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdullah Al‐Dhfyan. Abdullah Al‐Dhfyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Radwan, Awwad A., Fars K. Alanazi, & Abdullah Al‐Dhfyan. (2024). Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation. PLoS ONE. 19(4). e0298326–e0298326.
2.
Al‐Dhfyan, Abdullah, Ayodele Alaiya, Falah Almohanna, et al.. (2022). Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy. Journal of Advanced Research. 50. 177–192.
3.
Alhoshani, Ali, Moureq R. Alotaibi, Homood M. As Sobeai, et al.. (2021). In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis. Saudi Journal of Biological Sciences. 28(12). 7396–7403.
4.
Sobeai, Homood M. As, Khalid Alhazzani, Abdullah Al‐Dhfyan, et al.. (2021). Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies. Saudi Pharmaceutical Journal. 30(2). 138–149.
5.
Akhtar, Sabah, Lubna Therachiyil, Abdullah Al‐Dhfyan, et al.. (2020). Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway. Seminars in Cancer Biology. 83. 177–196.
6.
Farooq, Muhammad, Anamika Sharma, Zainab M. Almarhoon, et al.. (2019). Design and synthesis of mono-and di-pyrazolyl-s-triazine derivatives, their anticancer profile in human cancer cell lines, and in vivo toxicity in zebrafish embryos. Bioorganic Chemistry. 87. 457–464.
7.
Ashry, El Sayed H. El, Mohamed M. Said, Yasmine M. Abdel Aziz, et al.. (2018). Regio- and stereoselective synthesis of new spirooxindoles via 1,3-dipolar cycloaddition reaction: Anticancer and molecular docking studies. Journal of Photochemistry and Photobiology B Biology. 180. 98–108.
8.
Al‐Dhfyan, Abdullah, Ali Alhoshani, & Hesham M. Korashy. (2017). Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation. Molecular Cancer. 16(1). 14–14.
9.
Al-Ansary, Ghada H., Wagdy M. Eldehna, Hazem A. Ghabbour, et al.. (2017). Cancer stem cells CD133 inhibition and cytotoxicity of certain 3-phenylthiazolo[3,2- a ]benzimidazoles: design, direct synthesis, crystal study and in vitro biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. 32(1). 986–991.
10.
Said, Mohamed M., El Sayed H. El Ashry, El Sayed H. El Tamany, et al.. (2017). Synthesis of new spirooxindole-pyrrolothiazole derivatives: Anti-cancer activity and molecular docking. Bioorganic & Medicinal Chemistry. 25(4). 1514–1523.
11.
Bhat, M. A., Abdullah Al‐Dhfyan, & Mohamed A. Al‐Omar. (2016). Targeting Cancer Stem Cells with Novel 4-(4-Substituted phenyl)-5-(3,4,5-trimethoxy/3,4-dimethoxy)-benzoyl-3,4-dihydropyrimidine-2(1H)-one/thiones. Molecules. 21(12). 1746–1746.
12.
Radwan, Awwad A., Falah Almohanna, Fars K. Alanazi, Pulicat Manogaran, & Abdullah Al‐Dhfyan. (2016). Target β-catenin/CD44/Nanog axis in colon cancer cells by certain N′-(2-oxoindolin-3-ylidene)-2-(benzyloxy)benzohydrazides. Bioorganic & Medicinal Chemistry Letters. 26(7). 1664–1670.
13.
Elsaman, Tilal, Omar A. Al‐Deeb, Tarek Aboul‐Fadl, & Abdullah Al‐Dhfyan. (2016). Synthesis and antiproliferative activity of some novel amides of flufenamicacid and diclofenac. Der pharma chemica. 8(2). 434–443.
14.
Bhat, M. A., Abdullah Al‐Dhfyan, Ahmed M. Naglah, Azmat Ali Khan, & Mohamed A. Al‐Omar. (2015). Lead Optimization of 2-Cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides for Targeting the HER-2 Overexpressed Breast Cancer Cell Line SKBr-3. Molecules. 20(10). 18246–18263.
15.
Abdel‐Aziz, Hatem A., Hazem A. Ghabbour, Wagdy M. Eldehna, et al.. (2015). 2-((Benzimidazol-2-yl)thio)-1-arylethan-1-ones: Synthesis, crystal study and cancer stem cells CD133 targeting potential. European Journal of Medicinal Chemistry. 104. 1–10.
16.
Ghebeh, Hazem, Abdullah Al‐Dhfyan, Falah Almohanna, et al.. (2014). Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. British Journal of Cancer. 111(8). 1552–1561.
17.
Abdel‐Aziz, Hatem A., Tilal Elsaman, Abdullah Al‐Dhfyan, et al.. (2013). Synthesis and anticancer potential of certain novel 2-oxo-N'-(2-oxoindolin-3-ylidene)-2H-chromene-3-carbohydrazides. European Journal of Medicinal Chemistry. 70. 358–363.
18.
Radwan, Awwad A., Abdullah Al‐Dhfyan, Mohammed K. Abdel‐Hamid, Abdullah A. Al‐Badr, & Tarek Aboul‐Fadl. (2012). 3,5-Disubstituted thiadiazine-2-thiones: New cell-cycle inhibitors. Archives of Pharmacal Research. 35(1). 35–49.
19.
Al‐Dhfyan, Abdullah. (2012). Embryonic signature in breast cancers; Pluripotency roots of cancer stem cells. Saudi Pharmaceutical Journal. 21(2). 229–232.
20.
Sarhan, Abdelwareth A. O., Abdullah Al‐Dhfyan, Maha Al-Mozaini, Chaker N. Adra, & Tarek Aboul‐Fadl. (2010). Cell cycle disruption and apoptotic activity of 3-aminothiazolo[3,2-a]benzimidazole-2-carbonitrile and its homologues. European Journal of Medicinal Chemistry. 45(6). 2689–2694.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Riccardo Baruchello Breakdown of academic impact, for papers by Riccardo Rondanin Breakdown of academic impact, for papers by Mariusz Mojzych Breakdown of academic impact, for papers by Ahmed H.E. Hassan Breakdown of academic impact, for papers by San‐Qi Zhang Breakdown of academic impact, for papers by Subhas S. Karki Breakdown of academic impact, for papers by Jacques Fahy Breakdown of academic impact, for papers by Bahaa Elgendy Breakdown of academic impact, for papers by Haoliang Yuan Breakdown of academic impact, for papers by Dmitry A. Skvortsov